Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ANAPTYSBIO, INC Director's Dealing 2017

Jan 26, 2017

32596_dirs_2017-01-25_279dbf84-2764-4438-bf3c-c7da9e5086c1.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ANAPTYSBIO INC (ANAB)
CIK: 0001370053
Period of Report: 2017-01-25

Reporting Person: Topper James N (Director, 10% Owner)

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Series B Preferred Stock $0.00 Common Stock (1428571) Indirect
Series C Preferred Stock $0.00 Common Stock (604055) Indirect
Series C-1 Preferred Stock $0.00 Common Stock (195751) Indirect
Series D Preferred Stock $0.00 Common Stock (733740) Indirect
Series D Preferred Stock $0.00 Common Stock (209095) Indirect
Warrant to Purchase Series C Preferred Stock (right to buy) $4.55 2018-11-04 Series C Preferred Stock (117235) Indirect

Footnotes

F1: Each share of Preferred Stock will be automatically converted into one (1) share of Common Stock, for no additional consideration, immediately prior to the consummation of the Issuer's initial public offering, and has no expiration date.

F2: Represents shares held by Frazier Healthcare V, L.P., an affiliate of Frazier Healthcare Partners. Dr. Topper is a General Partner of Frazier Healthcare Partners.

F3: Represents shares held by Frazier Healthcare VII, L.P., an affiliate of Frazier Healthcare Partners. Dr. Topper is a General Partner of Frazier Healthcare Partners.

F4: Represents shares held by Frazier Healthcare VII-A, L.P., an affiliate of Frazier Healthcare Partners. Dr. Topper is a General Partner of Frazier Healthcare Partners.

F5: This warrant is exercisable at any time.